ZA978334B - Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications - Google Patents

Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications

Info

Publication number
ZA978334B
ZA978334B ZA978334A ZA978334A ZA978334B ZA 978334 B ZA978334 B ZA 978334B ZA 978334 A ZA978334 A ZA 978334A ZA 978334 A ZA978334 A ZA 978334A ZA 978334 B ZA978334 B ZA 978334B
Authority
ZA
South Africa
Prior art keywords
steriod
ifg
toxicity
treatment
kidney disorders
Prior art date
Application number
ZA978334A
Other languages
English (en)
Inventor
Philip D Acott
John F S Crocker
Original Assignee
Univ Dalhousie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Dalhousie filed Critical Univ Dalhousie
Publication of ZA978334B publication Critical patent/ZA978334B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA978334A 1996-09-16 1997-09-16 Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications ZA978334B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71033196A 1996-09-16 1996-09-16

Publications (1)

Publication Number Publication Date
ZA978334B true ZA978334B (en) 1999-03-16

Family

ID=24853590

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA978334A ZA978334B (en) 1996-09-16 1997-09-16 Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications

Country Status (7)

Country Link
US (2) US5985830A (xx)
EP (1) EP0956041A1 (xx)
AR (1) AR048563A1 (xx)
AU (1) AU4196697A (xx)
CA (1) CA2265972A1 (xx)
WO (1) WO1998011913A1 (xx)
ZA (1) ZA978334B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403764B1 (en) 1999-01-06 2002-06-11 Genentech, Inc. Insulin-like growth factor-1 protein variants
US6767892B1 (en) * 1997-11-07 2004-07-27 Chrion Corporation Compositions providing for increased IGF-I solubility
US6723557B1 (en) 1999-01-06 2004-04-20 California Institute Of Technology Caenorhabditis elegans LOV-1 gene
AU762047B2 (en) * 1999-01-06 2003-06-19 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
WO2001087323A2 (en) 2000-05-16 2001-11-22 Genentech, Inc. Method for treating cartilage disorders
EP1402266B1 (en) * 2000-11-28 2011-01-12 Premacure AB Reducing RISK OF COMPLICATIONS OF PREMATURITY
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ATE492610T1 (de) 2007-08-28 2011-01-15 Basf Se Photoaktives tio2 in beschichtungsmaterialien
ES2667066T3 (es) 2010-05-24 2018-05-09 The Trustees Of Columbia University In The City Of New York Proteínas NGAL mutantes y usos de las mismas
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
WO2019118272A1 (en) * 2017-12-11 2019-06-20 Mayo Foundation For Medical Education And Research Using probenecid to treat polycystic kidney disease
EP4228676A1 (en) * 2020-10-19 2023-08-23 Oak Hill Bio Limited Compositions suitable for use in neonates

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) * 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) * 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
HUT35524A (en) * 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPH0720993B2 (ja) * 1985-08-22 1995-03-08 グロペップ プロプライエタリー リミテッド 生長因子
SE8505922D0 (sv) * 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
AU607209B2 (en) * 1987-04-23 1991-02-28 Monsanto Technology Llc Secretion of insulin-like growth factor-i in e. coli
EP0346429B1 (en) * 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2)
DE68905203T2 (de) * 1988-02-05 1993-07-22 Ciba Geigy Ag Verwendung von igf i zur herstellung eines praeparates fuer die behandlung von nierenkrankheiten.
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ZA9010332B (en) * 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
US5128320A (en) * 1990-01-18 1992-07-07 Genentech, Inc. Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess by administering igf-i
TW270116B (xx) * 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
JPH05194254A (ja) * 1992-01-22 1993-08-03 Banyu Pharmaceut Co Ltd エンドセリンアンタゴニストを含有する抗高脂血症剤
SK128794A3 (en) * 1992-04-22 1995-03-08 Warner Lambert Co Peptides, method of their production and pharmaceutical agents on their base
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
TW287160B (xx) * 1992-12-10 1996-10-01 Hoffmann La Roche
EP0647449A1 (en) * 1993-06-24 1995-04-12 Takeda Chemical Industries, Ltd. Sustained-release preparation of anti-endothelin substance
TW394761B (en) * 1993-06-28 2000-06-21 Hoffmann La Roche Novel Sulfonylamino Pyrimidines
AU690941B2 (en) * 1993-11-15 1998-05-07 Celtrix Pharmaceuticals, Inc. Method of treating renal disease by administering IGF-I and IGFBP-3
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I

Also Published As

Publication number Publication date
CA2265972A1 (en) 1998-03-26
WO1998011913A1 (en) 1998-03-26
AU4196697A (en) 1998-04-14
EP0956041A1 (en) 1999-11-17
US6071880A (en) 2000-06-06
AR048563A1 (es) 2006-05-10
US5985830A (en) 1999-11-16

Similar Documents

Publication Publication Date Title
PH31420A (en) Methods of use for inhibiting bone loss and lowering serum cholesteol.
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
HUP1500179A2 (en) The use of human tnf-alpha binding antibodies
ZA978334B (en) Use of IFG-I for the treatment of kidney disorders renal insufficiencies steriod toxicity and related indications
IL130485A0 (en) New treatment for joint inflammation
AU5563398A (en) Use of mifepristone for the treatment of psychoses and addictive behaviours
IL125557A0 (en) Use of lhrh-analogs and anti-estrogens for treating gynaecological disorders
EP1030663A4 (en) TREATMENT OF FIBROMYALGIA AND RELATED DISEASES
HK1018271A1 (en) Substituted benzylamines and their use for the treatment of depression
AU4347696A (en) Use of mhc-ii binding and/or mhc-ii mimicking molecules for the prevention and/or treatment of inflammatory diseases
HU9700071D0 (en) Use of muramilpeptides
HK1022267A1 (en) Use of 1-hydroxy-2-pyridones for the treatment of saborrheic dermatitis
GB9615159D0 (en) Treatment of liquid
GB9620777D0 (en) Therapeutic use
ZA959766B (en) Screen of the type having two or more overlapping sliding leaves
GB2296660B (en) Flatus filters
GB9416410D0 (en) Effluent treatment
HU9500092D0 (en) Griddle apparatus for purifiing of wastewater
EP0941105A4 (en) PRE-TRAUMATIC USE OF HEMOGLOBIN
PT1011678E (pt) Utilização de mecamilamina para o tratamento de perturbações neuropsiquiátricas responsivas à nicotina.
AU4643799A (en) Hydrocolloids obtained from portulaca oleracea and the use thereof
GB9608389D0 (en) Treatment of spillages
GB9611871D0 (en) Improvements for the use of tissues
IL121229A0 (en) Hydrocolloids obtained from portulaca oleracea and the use thereof
HK1020382A1 (en) Block normalization processor